Sunday, 14 July 2019

GSK's ovarian cancer treatment meets main goal in late-stage study

GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.


No comments:

Post a Comment